Volume 16, Issue 8 (August 2018)                   IJRM 2018, 16(8): 491-496 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ebrahim Abadi Z, Khademi Bami M, Golzadeh M, Kalantar S M, Sheikhha M H. The frequency of TP53 R72P and MDM2 309T>G polymorphisms in Iranian infertile men with spermatogenetic failure: A case-control study. IJRM. 2018; 16 (8) :491-496
URL: http://journals.ssu.ac.ir/ijrmnew/article-1-1175-en.html
1- Department of Medical Genetics, Medical Faculty, Shahid Sadoughi University of Medical Sciences, Yazd, Iran, Iran
2- Medical Biotechnology Research Center, Ashkezar Branch, Islamic Azad University, Ashkezar, Yazd, Iran, Iran
3- Abortion Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran, Iran
4- Research and Clinical Center for Infertility, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran, Iran
5- Research and Clinical Center for Infertility, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran, Iran , sheikhha@yahoo.com
Abstract:   (140 Views)
Background: Tumor protein p53 (TP53) is a tumor suppressor transcriptional regulator protein which plays a critical role in the spermatogenesis. One of the most important regulators of p53 is Murine double minute 2 (MDM2), which acts as a negative regulator of the p53 pathway. Based on the key role of p53 and MDM2 in germ cell apoptosis, polymorphisms that cause a change in their function might affect germ cell apoptosis and the risk of male infertility. Objective: This study was designed to examine associations of TP53 72 Arg>Pro (rs1042522), and MDM2 309 T>G (rs937283) polymorphisms with spermatogenetic failure in an Iranian population.
Materials and Methods: A case-control study was conducted with 150 nonobstructive azoospermia or severe oligozoospermia and 150 fertile controls. The two polymorphisms, 72 Arg>Pro in TP53 and 309 T>G in MDM2, were genotyped using PCR-RFLP and ARMS-PCR respectively.
Results: Our analyses revealed that the allele and genotype frequencies of the TP53 R72P polymorphism were not significantly different between the cases and controls (p=0.41, p=0.40 respectively). Also, no significant differences were found in the allelic (p=0.46) and genotypic (p=0.78) distribution of MDM2 309 T>G polymorphism between patients and controls.
Conclusion: The results of this study indicate that polymorphisms of TP53 and MDM2 genes are unlikely to contribute to the pathogenesis of male infertility with spermatogenetic failure.
Full-Text [PDF 339 kb]   (35 Downloads) |   |   Full-Text (HTML)  (13 Views)  
Type of Study: Original Article |
Received: 2018/08/27 | Accepted: 2018/08/27 | Published: 2018/08/27

1. Hamada A, Esteves SC, Agarwal A. Genetics and male infertility. Infertility-Diagnosis, Management & IVF. 1st Ed. New Delhi, Jaypee Brothers Medical Publishers; 2012: 113-160. [DOI:10.5005/jp/books/11639_7]
2. Sadeghi-Nejad H, Farrokhi F. Genetics of azoospermia: current knowledge, clinical implications, and future directions. Part II: Y chromosome microdeletions. Urol J 2007; 4: 192-206.
3. Yin Y, Stahl BC, DeWolf WC, Morgentaler A. p53-mediated germ cell quality control in spermatogenesis. Dev Biol 1998; 204: 71-165. [DOI:10.1006/dbio.1998.9074]
4. Sinha Hikim AP, Swerdloff RS. Hormonal and genetic control of germ cell apoptosis in the testis. Rev Reprod 1999; 4: 38-47. [DOI:10.1530/ror.0.0040038]
5. Neto FT, Bach PV, Najari BB, Li PS, Goldstein M. Spermatogenesis in humans and its affecting factors. Semin Cell Dev Biol 2016; 59: 10-26. [DOI:10.1016/j.semcdb.2016.04.009]
6. Beumer TL, Roepers-Gajadien HL, Gademan IS, Van Buul PP, Gil-Gomez G, Rutgers DH, et al. The role of the tumor suppressor p53 in spermatogenesis. Cell Death Differ 1998; 5: 669-677. [DOI:10.1038/sj.cdd.4400396]
7. Oren M, Rotter V. Introduction: p53-the first twenty years. Cell Mol Life Sci 1999; 55: 9-11. [DOI:10.1007/s000180050265]
8. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387: 299-303. [DOI:10.1038/387299a0]
9. Mashayekhi F, Hadiyan S. A single-nucleotide polymorphism in TP53 may be a genetic risk factor for Iranian patients with idiopathic male infertility. Andrologia 2012; 44 (Suppl.): 560-564. [DOI:10.1111/j.1439-0272.2011.01227.x]
10. Rasti M, Kalantar S, Sheikhha M. The higher rate of SNP of H2BFWT gene in an Iranian population with idiopathic spermatogenesis impairment. Iran J Reprod Med 2013: 64.
11. Khademi Bami M, Dehghan Tezerjani M, Montazeri F, Ashrafzadeh Mehrjardi HR, Ghasemi-Esmailabad S, Sheikhha MH, et al. Tumor necrosis factor alpha-308 G/A single nucleotide polymorphism and risk of sperm abnormalities in Iranian males. Int J Fertil Steril 2017; 11: 112-116.
12. Chan Y, Jiang H, Ma L, Chen J, Li D, Meng Y, et al. No association of TP 53 codon 72 SNP with male infertility: a study in a Chinese population and a meta-analysis. Syst Biol Reprod Med 2015; 61: 222-227. [DOI:10.3109/19396368.2015.1017667]
13. Murphy ME. Polymorphic variants in the p53 pathway. Cell Death Diff 2006; 13: 916-920. [DOI:10.1038/sj.cdd.4401907]
14. Hu W, Feng Z, Atwal GS, Levine AJ. p53: a new player in reproduction. Cell Cycle 2008; 7: 848-852. [DOI:10.4161/cc.7.7.5658]
15. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119: 591-602. [DOI:10.1016/j.cell.2004.11.022]
16. Bhowmik A, Das S, Bhattacharjee A, Choudhury B, Naiding M, Deka S, et al. MDM2 and TP53 polymorphisms as predictive markers for head and neck cancer in Northeast Indian population: effect of gene-gene and gene-environment interactions. Asian Pac J Cancer Prev 2015; 16: 5767-5772. [DOI:10.7314/APJCP.2015.16.14.5767]
17. Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 2005; 65: 9582-9587. [DOI:10.1158/0008-5472.CAN-05-1460]
18. Yang M, Guo Y, Zhang X, Miao X, Tan W, Sun T, et al. Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis 2007; 28: 1996-2001. [DOI:10.1093/carcin/bgm168]
19. Zhang X, Miao X, Guo Y, Tan W, Zhou Y, Sun T, et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 2006; 27: 110-117. [DOI:10.1002/humu.20277]
20. Qiu M, Liu Y, Yu X, Qin L, Bei C, Zeng X, et al. Interaction between p53 codon 72 and MDM2 309T> G polymorphisms and the risk of hepatocellular carcinoma. Tumour Biol 2016; 37: 3863-3870. [DOI:10.1007/s13277-015-4222-4]
21. Ghasemi N, Karimi-Zarchi M, Mortazavi-Zadeh MR, Atash-Afza A. Evaluation of the frequency of TP53 gene codon 72 polymorphisms in Iranian patients with endometrial cancer. Cancer Genet Cytogenet 2010; 196: 167-170. [DOI:10.1016/j.cancergencyto.2009.09.013]
22. Ota M, Fukushima H, Kulski JK, Inoko H. Single nucleotide polymorphism detection by polymerase chain reaction-restriction fragment length polymorphism. Nat Protoc 2007; 2: 2857-2864. [DOI:10.1038/nprot.2007.407]
23. Ye S, Dhillon S, Ke X, Collins AR, Day IN. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res 2001; 29: e88-e95. [DOI:10.1093/nar/29.17.e88]
24. Xiao M, Zhang L, Zhu X, Huang J, Jiang H, Hu S, et al. Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population. BMC Cancer 2010; 10: 147-153. [DOI:10.1186/1471-2407-10-147]
25. Huang C, Liu W, Ji GX, Gu AH, Qu JH, Song L, et al. Genetic variants in TP53 and MDM2 associated with male infertility in Chinese population. Asian J Androl 2012; 14: 691-694. [DOI:10.1038/aja.2012.39]
26. Lu NX, Xia YK, Gu AH, Liang J, Wang SL, Wang XR. Lack of association between polymorphisms in p53 gene and spermatogenetic failure in a Chinese population. Andrologia 2007; 39: 223-228. [DOI:10.1111/j.1439-0272.2007.00790.x]
27. Jin Q, Wang B, Wang J, Liu T, Yu X, Jia C ,et al. Association between TP53 gene Arg72Pro polymorphism and idiopathic infertility in southeast Chinese Han males. Syst Biol Reprod Med 2013; 59: 342-346. [DOI:10.3109/19396368.2013.818743]
28. Avirmed S, Wang BS, Selenge B, Sanjaajamts A, Ganbat B, Erdenebileg U, et al. Association between MDM2-SNP309 and p53R72P polymorphisms and the risk of bladder cancer in the Mongolian population. Mol Clin Oncol 2017; 7: 412-420. [DOI:10.3892/mco.2017.1317]
29. El-Danasouri NM, Ragab SH, Rasheed MA, Ali El Saadany Z, Abd El-Fattah SN. MDM2 SNP309 and p53 codon 72 genetic polymorphisms and risk of AML: an Egyptian study. Ann Clin Lab Sci 2014; 44: 449-454.
30. Sheikhha MH, Zaimy MA, Soleimanian S, Kalantar SM, Rasti A, Golzade M, et al. Multiplex PCR Screening of Y-chromosome microdeletions in azoospermic ICSI candidate men. Iran J Reprod Med 2013; 11: 335-338.
31. Miyamoto T, Minase G, Okabe K, Ueda H, Sengoku K. Male infertility and its genetic causes. J Obstet Gynaecol Res 2015; 41: 1501-1505. [DOI:10.1111/jog.12765]

Add your comments about this article : Your username or Email:

Send email to the article author

© 2018 All Rights Reserved | International Journal of Reproductive BioMedicine

Designed & Developed by : Yektaweb